In Vivo CAR-T: Stress-Testing the Lilly–Kelonia Deal with AI-Powered Wargaming
Why the Lilly–Kelonia Deal Matters for In Vivo CAR-T Download the…
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…
Cell and Gene Therapy Today—March 19, 2026
This week’s Gene and Cell Therapy update highlights clinical progress,…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
Cell and Gene Therapy Today—November 20, 2025
This weekly Cell & Gene Therapy update spans regulatory actions, durable…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A Professional…
Cell and Gene Therapy Video Recap – October 16, 2025
Here’s your biweekly look at the latest breakthroughs in Cell and Gene Therapy.…
Cell and Gene Therapy Weekly News - October 9th 2025
Gene & Cell Therapy Update: JCR CNS/Muscle AAV, Lexeo FA Data, RareTx…
ESGCT 2025 Preview: Key Gene & Cell Therapy Highlights to Watch
ESGCT 2025 at a glance Ahead of ESGCT 2025, LucidQuest outlines the…
Neuroscience Weekly News - September 17th 2025
🧠 This Week in Neuroscience: RNAi Tau Therapy CTA, MS Patent Win, Generic…